CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
TCR-T 细胞治疗 AML/MDS 的现状与挑战
英文原题：Current status and challenges of TCR-T cell therapy for AML/MDS.
查看英文原题
Current status and challenges of TCR-T cell therapy for AML/MDS.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管近期有新型药物进入临床，急性髓系白血病（AML）和骨髓增生异常综合征（MDS）的生存率仍不理想，因此亟需开发作用机制不同的新策略。由于缺乏广泛且均一表达的细胞表面靶点，且患者资格还受到HLA限制，AML/MDS免疫治疗的可行性低于B细胞恶性肿瘤。根据AML/MDS细胞中靶抗原的高水平且均一表达谨慎选择患者，可能有助于作为生物标志物。本综述首先介绍T细胞受体（TCR）T细胞疗法的开发流程，随后回顾近期临床试验及未来展望。
展开英文摘要原文
Although novel drugs have recently been introduced in the clinic, the survival rates of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are not yet satisfactory; thus, developing novel strategies with different modes of action is urgently needed. Immunotherapy against AML/MDS is less feasible than that for B-cell malignancies because commonly and uniformly expressed cell-surface targets are lacking, and HLA constraints further limit patient eligibility.
Careful patient selection based on high and homogeneous target antigen expression in AML/MDS cells may serve as a biomarker. In this review, we first describe T-cell receptor (TCR) T-cell therapy development processes, then review recent clinical trials and future perspectives.
论文信息
- 作者
- Akatsuka Y
- 单位
- Department of Immunology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Japan. yos-akatsuk@umin.ac.jp.Japan
- 文献类型
- 综述
- 期刊
- International journal of hematology2026 Jun 18
- 原文标识
- PubMed 42315760 · DOI 10.1007/s12185-026-04239-6